/ 2 items

#VCYT↓

VCYT/ 09/15/2026 · 6:50 AM

Veracyte Buys Convergent Genomics for Up to $180 Million, Adding a Urine Test for Bladder Cancer

Veracyte acquired Convergent Genomics for $150M cash plus up to $30M in milestones, adding UroAmp, a urine tumor DNA test for bladder cancer.

BHVN/ 04/13/2026 · 12:02 PM

Analysts Turn Bullish on Biohaven, Caris, and Veracyte

Canaccord says Biohaven is undervalued and could rise on epilepsy trial results. Jefferies likes Caris Life Sciences and Veracyte, citing strong growth in cancer diagnostics and solid finances.